CVHNLC + pembrolizumab + carboplatin + paclitaxel

**CVHNLC + pembrolizumab + carboplatin + paclitaxel** is a four-drug combination therapy. CVHNLC is a code name with no further details found in currently available clinical literature or databases, suggesting it may be an investigational product, possibly under evaluation in conjunction with the immunotherapy pembrolizumab (an anti-PD-1 monoclonal antibody) plus the chemotherapeutic agents carboplatin (a platinum-based DNA-damaging small molecule) and paclitaxel (a taxane class microtubule-stabilizing agent). - **Pembrolizumab** blocks PD-1 on T cells, enhancing anti-tumor immune activity, approved for a variety of cancers. - **Carboplatin** is a DNA crosslinker, inhibiting DNA synthesis and function in cancer cells, used routinely in ovarian and lung cancer. - **Paclitaxel** interferes with microtubule function, inhibiting cell division, widely used in solid tumors including ovarian, lung, and breast cancer. This specific four-drug regimen may be under evaluation for cancer treatment as part of clinical trials, especially in solid tumor oncology.